Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TXN | P10599 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012590 | 0.76 | KIF11 (0.43) | ADORA3ADORA2AADORA1PKMELANE | |
| SCHEMBL6759198 | 0.76 | ADORA3 (0.40) | ADORA3ADORA2AADORA1ALDH1A1L3MBTL1 | |
| SCHEMBL17011661 | 0.76 | PARP1 (0.56) | ADORA3ADORA2AADORA1ELANEALDH1A1 | |
| SCHEMBL22648611 | 0.75 | PARP1 (0.39) | ADORA3ADORA2AADORA1ALDH1A1L3MBTL1 | |
| SCHEMBL10779491 | 0.75 | PKM (0.70) | PKMELANEALDH1A1TNKS2TNKS | |
| SCHEMBL22648457 | 0.75 | PARP1 (0.39) | ADORA3ADORA2AADORA1PKMALDH1A1 | |
| SCHEMBL25890965 | 0.74 | JAK2 (0.47) | ADORA3ADORA2AADORA1PKMELANE | |
| SCHEMBL12057078 | 0.74 | MEN1 (0.44) | ADORA3ADORA2AADORA1PKMELANE | |
| SCHEMBL4728675 | 0.73 | KDM5B (0.43) | ADORA3ADORA2AADORA1ALDH1A1PARP1 | |
| SCHEMBL12261357 | 0.73 | MAPT (0.46) | ADORA3ADORA2AADORA1ELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399444-B2 | Bicyclic imidazole as DP1 receptor antagonists | GlaxoSmithKline Intellectual Property Development Ltd. (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399444-B2 | Bicyclic imidazole as DP1 receptor antagonists | GlaxoSmithKline Intellectual Property Development Ltd. (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-2373628-B1 | Bicyclic imidazole derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| US-20110245310-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2011-10-06 | — | — | US | disclosed |
| US-20110245310-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2011-10-06 | — | — | US | disclosed |
| WO-2010070021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245310-A1 | Novel Compounds | HRH1, CMA1, HRH4 | ADORA3 936/4885ADORA2A 1652/4885ADORA1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.